Across TCGA pan-cancer cohorts, SZT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SZT2 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SZT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SZT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where SZT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.627	0.903	.003	21	view →
LSCC	DFS	Tertile	All	0.474	0.988	.016	13	view →
CCRCC	OS	Median	All	1.000	0.672	.011	8	view →
LUAD	OS	Tertile	III,IV	1.000	0.486	.017	6	view →
PDAC	DFS	Quartile	II,III,IV	0.262	0.543	.029	5	view →
GBM	OS	Median	All	0.277	0.498	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: SZT2 tumor-vs-normal RNA expression · all SZT2 data types